JP2007515400A5 - - Google Patents

Download PDF

Info

Publication number
JP2007515400A5
JP2007515400A5 JP2006540401A JP2006540401A JP2007515400A5 JP 2007515400 A5 JP2007515400 A5 JP 2007515400A5 JP 2006540401 A JP2006540401 A JP 2006540401A JP 2006540401 A JP2006540401 A JP 2006540401A JP 2007515400 A5 JP2007515400 A5 JP 2007515400A5
Authority
JP
Japan
Prior art keywords
diseases
treatment
novel
present
growth factor
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
JP2006540401A
Other languages
English (en)
Japanese (ja)
Other versions
JP2007515400A (ja
Filing date
Publication date
Priority claimed from GB0327734A external-priority patent/GB0327734D0/en
Priority claimed from GB0417805A external-priority patent/GB0417805D0/en
Application filed filed Critical
Priority claimed from PCT/EP2004/013459 external-priority patent/WO2005051366A2/en
Publication of JP2007515400A publication Critical patent/JP2007515400A/ja
Publication of JP2007515400A5 publication Critical patent/JP2007515400A5/ja
Ceased legal-status Critical Current

Links

JP2006540401A 2003-11-28 2004-11-26 タンパク質キナーゼ依存性疾患の処置におけるジアリール尿素誘導体 Ceased JP2007515400A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB0327734A GB0327734D0 (en) 2003-11-28 2003-11-28 Organic compounds
GB0417805A GB0417805D0 (en) 2004-08-10 2004-08-10 Organic compounds
PCT/EP2004/013459 WO2005051366A2 (en) 2003-11-28 2004-11-26 Diaryl urea derivatives in the treatment of protein kinase dependent diseases

Publications (2)

Publication Number Publication Date
JP2007515400A JP2007515400A (ja) 2007-06-14
JP2007515400A5 true JP2007515400A5 (enExample) 2008-01-17

Family

ID=34635447

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2006540401A Ceased JP2007515400A (ja) 2003-11-28 2004-11-26 タンパク質キナーゼ依存性疾患の処置におけるジアリール尿素誘導体

Country Status (12)

Country Link
US (1) US20080312192A1 (enExample)
EP (1) EP1689376A2 (enExample)
JP (1) JP2007515400A (enExample)
KR (1) KR20060110307A (enExample)
AR (1) AR047496A1 (enExample)
AU (2) AU2004292773A1 (enExample)
BR (1) BRPI0416935A (enExample)
CA (1) CA2546673A1 (enExample)
PE (1) PE20051046A1 (enExample)
RU (1) RU2006122853A (enExample)
TW (1) TW200529849A (enExample)
WO (1) WO2005051366A2 (enExample)

Families Citing this family (80)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HU230302B1 (hu) 2000-10-20 2015-12-28 Eisai R&D Management Co., Ltd. Nitrogéntartalmú aromás származékok és ezeket tartalmazó gyógyászati készítmények
TWI329105B (en) 2002-02-01 2010-08-21 Rigel Pharmaceuticals Inc 2,4-pyrimidinediamine compounds and their uses
ATE451104T1 (de) 2002-07-29 2009-12-15 Rigel Pharmaceuticals Inc Verfahren zur behandlung oder pruvention von autoimmunkrankheiten mit 2,4-pyrimidindiamin- verbindungen
ATE508747T1 (de) 2003-03-10 2011-05-15 Eisai R&D Man Co Ltd C-kit kinase-hemmer
ES2421139T3 (es) 2003-07-30 2013-08-29 Rigel Pharmaceuticals, Inc. Compuestos de 2,4-pirimidindiamina para su uso en el tratamiento o la prevención de enfermedades autoinmunitarias
CN100450998C (zh) 2003-11-11 2009-01-14 卫材R&D管理有限公司 脲衍生物的制备方法
AU2011253934C1 (en) * 2004-06-17 2013-08-22 Cytokinetics, Inc. Substituted urea derivatives for treating cardiac diseases
US7507735B2 (en) 2004-06-17 2009-03-24 Cytokinetics, Inc. Compounds, compositions and methods
GB0512324D0 (en) * 2005-06-16 2005-07-27 Novartis Ag Organic compounds
EP1797881B1 (en) 2004-09-17 2009-04-15 Eisai R&D Management Co., Ltd. Medicinal composition with improved stability and reduced gelation properties
EP2161275A1 (en) 2005-01-19 2010-03-10 Rigel Pharmaceuticals, Inc. Prodrugs of 2,4-pyrimidinediamine compounds and their uses
US7491732B2 (en) 2005-06-08 2009-02-17 Rigel Pharmaceuticals, Inc. Compositions and methods for inhibition of the JAK pathway
US20070203161A1 (en) 2006-02-24 2007-08-30 Rigel Pharmaceuticals, Inc. Compositions and methods for inhibition of the jak pathway
EP2281901B1 (en) 2005-08-02 2013-11-27 Eisai R&D Management Co., Ltd. Anti-tumour pharmaceutical composition with angiogenesis inhibitors
AR058347A1 (es) 2005-12-15 2008-01-30 Cytokinetics Inc Entidades quimias composiciones y metodos
EP1962852B1 (en) 2005-12-19 2017-01-25 Cytokinetics, Inc. Compounds, compositions and methods
MEP3808A (xx) 2005-12-21 2010-02-10 Novartis Ag Derivati pirimidinil aril uree kao fgf inhibitori
TW200804349A (en) * 2005-12-23 2008-01-16 Kalypsys Inc Novel substituted pyrimidinyloxy ureas as inhibitors of protein kinases
DK1973545T3 (da) 2005-12-23 2013-02-25 Ariad Pharma Inc Bicykliske heteroarylforbindelser
WO2007098507A2 (en) 2006-02-24 2007-08-30 Rigel Pharmaceuticals, Inc. Compositions and methods for inhibition of the jak pathway
GB0605120D0 (en) 2006-03-14 2006-04-26 Novartis Ag Organic Compounds
AU2007249924B2 (en) 2006-05-08 2013-07-04 Ariad Pharmaceuticals, Inc. Acetylenic heteroaryl compounds
EP2036557B1 (en) * 2006-05-18 2015-10-21 Eisai R&D Management Co., Ltd. Antitumor agent for thyroid cancer
EP2069535B1 (en) * 2006-08-11 2013-04-10 Johns Hopkins University Consensus coding sequences of human breast and colorectal cancers
CN101511793B (zh) 2006-08-28 2011-08-03 卫材R&D管理有限公司 针对未分化型胃癌的抗肿瘤剂
AU2013231117B2 (en) * 2006-12-14 2016-06-02 Janssen Pharmaceutica N.V. Process for the preparation of piperazinyl and diazepanyl benzamide derivatives
EP2102173B1 (en) * 2006-12-22 2010-10-20 F. Hoffmann-La Roche AG Pyrimidyl derivatives as protein kinase inhibitors
AU2008211952B2 (en) 2007-01-29 2012-07-19 Eisai R & D Management Co., Ltd. Composition for treatment of undifferentiated-type of gastric cancer
GB0706932D0 (en) * 2007-04-10 2007-05-16 Univ London Pharmacy Ureylene derivatives
EP2146964A2 (en) 2007-04-17 2010-01-27 Novartis Ag Ethers of naphtalene carboxylic acid amides as cancer cure
FR2921657A1 (fr) * 2007-09-28 2009-04-03 Sanofi Aventis Sa Derives de nicotinamide, leur preparation et leur application en therapeutique
US7989465B2 (en) 2007-10-19 2011-08-02 Avila Therapeutics, Inc. 4,6-disubstituted pyrimidines useful as kinase inhibitors
CA2702674C (en) * 2007-10-19 2016-05-03 Avila Therapeutics, Inc. Heteroaryl compounds and uses thereof
JP5638244B2 (ja) 2007-11-09 2014-12-10 エーザイ・アール・アンド・ディー・マネジメント株式会社 血管新生阻害物質と抗腫瘍性白金錯体との併用
EP2070929A1 (en) 2007-12-11 2009-06-17 Bayer Schering Pharma Aktiengesellschaft Alkynylaryl compounds and salts thereof, pharmaceutical compositions comprising same, methods of preparing same and uses of same
JP2011520809A (ja) * 2008-05-05 2011-07-21 アムジエン・インコーポレーテツド γセクレターゼモジュレーターとしての尿素化合物
FR2943669B1 (fr) * 2009-03-24 2011-05-06 Sanofi Aventis Derives de nicotinamide,leur preparation et leur application en therapeutique
CN101671301B (zh) * 2009-05-05 2014-02-26 江苏省药物研究所有限公司 杂环取代的二苯脲类衍生物及其用途
AR077468A1 (es) 2009-07-09 2011-08-31 Array Biopharma Inc Compuestos de pirazolo (1,5 -a) pirimidina sustituidos como inhibidores de trk- quinasa
CN105693720B (zh) 2010-05-20 2019-01-18 阵列生物制药公司 作为trk激酶抑制剂的大环化合物
MX2012014776A (es) 2010-06-25 2013-01-29 Eisai R&D Man Co Ltd Agente antitumoral que emplea compuestos con efecto inhibidor de cinasas combinados.
FR2965263A1 (fr) 2010-09-24 2012-03-30 Sanofi Aventis Derives de thienopyridine nicotinamide, leur preparation et leur application en therapeutique
FR2965262A1 (fr) 2010-09-24 2012-03-30 Sanofi Aventis Derives de nicotinamide, leur preparation et leur application en therapeutique
MX2013009931A (es) 2011-04-18 2013-10-01 Eisai R&D Man Co Ltd Agentes terapeuticos contra tumores.
US9945862B2 (en) 2011-06-03 2018-04-17 Eisai R&D Management Co., Ltd. Biomarkers for predicting and assessing responsiveness of thyroid and kidney cancer subjects to lenvatinib compounds
EP2760843B1 (en) 2011-09-26 2016-03-02 Bristol-Myers Squibb Company Selective nr2b antagonists
CN103508961B (zh) 2012-06-26 2015-07-22 中美冠科生物技术（太仓）有限公司 抗肿瘤药物
CA3022250A1 (en) 2012-12-12 2014-06-12 Ariad Pharmaceuticals, Inc. Crystalline forms of 3-(imidazo[1,2-b]pyridazin-3-ylethynyl)-4-methyl-n-{4-[(4-methylpiperazin-1-yl)methyl]-3-(trifluoromethyl)phenyl}benzamide mono hydrochloride
US9334239B2 (en) 2012-12-21 2016-05-10 Eisai R&D Management Co., Ltd. Amorphous form of quinoline derivative, and method for producing same
DK2981535T3 (da) 2013-04-02 2021-03-01 Oxular Acquisitions Ltd Urinstofderivater, der er anvendelige som kinaseinhibitorer
US10517861B2 (en) 2013-05-14 2019-12-31 Eisai R&D Management Co., Ltd. Biomarkers for predicting and assessing responsiveness of endometrial cancer subjects to lenvatinib compounds
EP3083604A1 (en) * 2013-12-20 2016-10-26 Respivert Limited Urea derivatives useful as kinase inhibitors
CN106660964B (zh) 2014-08-28 2021-09-03 卫材R&D管理有限公司 高纯度喹啉衍生物及其生产方法
MA40775A (fr) 2014-10-01 2017-08-08 Respivert Ltd Dérivé d'acide 4-(4-(4-phényluréido-naphtalén -1-yl) oxy-pyridin-2-yl) amino-benzoïque utilisé en tant qu'inhibiteur de la kinase p38
TWI746426B (zh) 2014-11-16 2021-11-21 美商亞雷生物製藥股份有限公司 (S)-N-(5-((R)-2-(2,5-二氟苯基)-吡咯啶-1-基)-吡唑并[1,5-a]嘧啶-3-基)-3-羥基吡咯啶-1-甲醯胺硫酸氫鹽結晶型
PL3263106T3 (pl) 2015-02-25 2024-04-02 Eisai R&D Management Co., Ltd. Sposób tłumienia goryczy pochodnej chinoliny
KR102662228B1 (ko) 2015-03-04 2024-05-02 머크 샤프 앤드 돔 코포레이션 암을 치료하기 위한 pd-1 길항제 및 vegfr/fgfr/ret 티로신 키나제 억제제의 조합
ES2886107T3 (es) 2015-06-16 2021-12-16 Prism Biolab Co Ltd Antineoplásico
EP3322706B1 (en) 2015-07-16 2020-11-11 Array Biopharma, Inc. Substituted pyrazolo[1,5-a]pyridine compounds as ret kinase inhibitors
AU2016309356B2 (en) 2015-08-20 2021-06-24 Eisai R&D Management Co., Ltd. Tumor therapeutic agent
TN2018000138A1 (en) 2015-10-26 2019-10-04 Array Biopharma Inc Point mutations in trk inhibitor-resistant cancer and methods relating to the same
US10045991B2 (en) 2016-04-04 2018-08-14 Loxo Oncology, Inc. Methods of treating pediatric cancers
HUE068971T2 (hu) 2016-04-04 2025-02-28 Loxo Oncology Inc (S)-N-(5-((R)-2-(2,5-difluorofenil)-pirrolidin-1-il)-pirazolo[1,5-A]pirimidin-3-il) -3-hidroxipirrolidin-1-karboxamid folyékony készítményei
RS65988B1 (sr) 2016-04-04 2024-10-31 Loxo Oncology Inc Postupak lečenja pedijatrijskih karcinoma
SI3458456T1 (sl) 2016-05-18 2021-04-30 Loxo Oncology, Inc. Priprava (S)-N-(5-((R)-2-(2,5-difluorofenil) pirolidin-1-il) pirazolo (1,5-A) pirimidin-3-il)-3-hidroksipirolidin-1-karboksamida
JOP20190077A1 (ar) 2016-10-10 2019-04-09 Array Biopharma Inc مركبات بيرازولو [1، 5-a]بيريدين بها استبدال كمثبطات كيناز ret
TWI704148B (zh) 2016-10-10 2020-09-11 美商亞雷生物製藥股份有限公司 作為ｒｅｔ激酶抑制劑之經取代吡唑并[1,5-a]吡啶化合物
JOP20190092A1 (ar) 2016-10-26 2019-04-25 Array Biopharma Inc عملية لتحضير مركبات بيرازولو[1، 5-a]بيريميدين وأملاح منها
WO2018136663A1 (en) 2017-01-18 2018-07-26 Array Biopharma, Inc. Ret inhibitors
CN110267960B (zh) 2017-01-18 2022-04-26 阿雷生物药品公司 作为RET激酶抑制剂的取代的吡唑并[1,5-a]吡嗪化合物
MX380144B (es) 2017-02-08 2025-03-12 Eisai R&D Man Co Ltd Composicion farmaceutica de tratamiento de tumores.
JOP20190213A1 (ar) 2017-03-16 2019-09-16 Array Biopharma Inc مركبات حلقية ضخمة كمثبطات لكيناز ros1
CA3061888A1 (en) 2017-05-16 2018-11-22 Eisai R&D Management Co., Ltd. Treatment of hepatocellular carcinoma
TWI812649B (zh) 2017-10-10 2023-08-21 美商絡速藥業公司 6-(2-羥基-2-甲基丙氧基)-4-(6-(6-((6-甲氧基吡啶-3-基)甲基)-3,6-二氮雜雙環[3.1.1]庚-3-基)吡啶-3-基)吡唑并[1,5-a]吡啶-3-甲腈之調配物
TWI791053B (zh) 2017-10-10 2023-02-01 美商亞雷生物製藥股份有限公司 6-(2-羥基-2-甲基丙氧基)-4-(6-(6-((6-甲氧基吡啶-3-基)甲基)-3,6-二氮雜雙環[3.1.1]庚-3-基)吡啶-3-基)吡唑并[1,5-a]吡啶-3-甲腈之結晶形式及其醫藥組合物
AU2017444054B2 (en) * 2017-12-21 2021-10-07 Hefei Institutes Of Physical Science, Chinese Academy Of Sciences Class of pyrimidine derivative kinase inhibitors
WO2019143994A1 (en) 2018-01-18 2019-07-25 Array Biopharma Inc. Substituted pyrazolyl[4,3-c]pyridinecompounds as ret kinase inhibitors
CN111971286B (zh) 2018-01-18 2023-04-14 阿雷生物药品公司 作为RET激酶抑制剂的取代的吡咯并[2,3-d]嘧啶化合物
TW201938169A (zh) 2018-01-18 2019-10-01 美商亞雷生物製藥股份有限公司 作為RET激酶抑制劑之經取代吡唑并[3,4-d]嘧啶化合物
ES2922314T3 (es) 2018-09-10 2022-09-13 Array Biopharma Inc Compuestos heterocíclicos condensados como inhibidores de cinasa RET

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU594098B2 (en) * 1985-12-11 1990-03-01 Ishihara Sangyo Kaisha Ltd. N-benzoyl urea compounds, antitumorous compositions containing them, and process for their preparation
EP1042305B1 (en) * 1997-12-22 2005-06-08 Bayer Pharmaceuticals Corp. INHIBITION OF p38 KINASE USING SYMMETRICAL AND UNSYMMETRICAL DIPHENYL UREAS
US7928239B2 (en) * 1999-01-13 2011-04-19 Bayer Healthcare Llc Inhibition of RAF kinase using quinolyl, isoquinolyl or pyridyl ureas
EP1140840B1 (en) * 1999-01-13 2006-03-22 Bayer Pharmaceuticals Corp. -g(v)-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors
HU230302B1 (hu) * 2000-10-20 2015-12-28 Eisai R&D Management Co., Ltd. Nitrogéntartalmú aromás származékok és ezeket tartalmazó gyógyászati készítmények
JP2005531488A (ja) * 2001-10-09 2005-10-20 ザ・ユニバーシティ・オブ・シンシナティ 甲状腺癌を処置するためのｅｇｆ受容体阻害剤
AU2003209116A1 (en) * 2002-02-11 2003-09-04 Bayer Pharmaceuticals Corporation Aryl ureas with angiogenesis inhibiting activity
PE20040522A1 (es) * 2002-05-29 2004-09-28 Novartis Ag Derivados de diarilurea dependientes de la cinasa de proteina
PT1636585E (pt) * 2003-05-20 2008-03-27 Bayer Pharmaceuticals Corp Diarilureias com actividade inibidora de cinase
NZ544920A (en) * 2003-07-23 2009-11-27 Bayer Healthcare Llc 4{4-[3-(4-chloro-3-trifluoromethylphenyl)-ureido]-3-fluorophenoxy}-pyridine-2-carboxylic acid methylamide and metabolites for the treatment and prevention of diseases and conditions

Similar Documents

Publication Publication Date Title
JP2007515400A5 (enExample)
RU2416611C2 (ru) Бициклические амиды как ингибиторы киназы
JP2006502183A5 (enExample)
NO20082026L (no) Deazapuriner som er nyttige som inhibitorer for Janus-kinaser
DE602007007985D1 (de) Als inhibitoren von proteinkinasen geeignete aminopyrimidine
ATE466580T1 (de) Azolylaminoazine als proteinkinasehemmer
ATE468336T1 (de) Azolylaminoazine als proteinkinasehemmer
ATE365733T1 (de) Zusammensetzungen brauchbar als protein-kinase- inhibitoren
ATE482213T1 (de) Als inhibitoren von proteinkinasen geeignete pyrazoloä1,5-aüpyrimidine
NO20071915L (no) Diaminotriazolforbindelser nyttige som proteinkinaseinhibitorer
NO20074431L (no) Pyrrolopyrimidiner nyttige som proteinkinaseinhibitorer
JP2007522094A5 (enExample)
ATE451376T1 (de) Zusammensetzungen, die sich als inhibitoren von proteinkinasen eignen
DE602004024374D1 (de) Zusammensetzungen zur verwendung als protein-kinase-inhibitoren
WO2007084557A3 (en) Azaindoles useful as inhibitors of janus kinases
NO20051985L (no) Indazoler, benzotiazoler og benzoisotiazoler, samt fremstilling og anvendelser derav.
TW200736249A (en) Aminopyrimidines useful as kinase inhibitors
EA200602062A1 (ru) Амидосоединения и их применение в качестве фармацевтических средств
MX2007014619A (es) Pirrolopiridinas de utilidad como inhibidores de proteina quinasa.
NO20073140L (no) Pyrrolopyraziner og pyralopyraziner som er nyttige som inhibitorer av proteinkinaser
EA200602196A1 (ru) Производные пиразола, композиции, содержащие эти соединения, и способы применения
ATE470443T1 (de) Indol-1-yl-essigsäurederivate
WO2005016966A3 (en) Intron fusion proteins, and methods of identifying and using same
NO20070502L (no) Azaindoler nyttige som inhibitorer av proteinkinaser
WO2005018605A3 (en) Novel formulation of ropinirole